Sacituzumab Govitecan Shows Superior Efficacy Over Standard Chemotherapy in Metastatic HR+/HER2- Breast Cancer
In an eye-opening development, sacituzumab govitecan has been shown to outperform standard chemotherapy in treating patients with HR+, HER2- metastatic breast cancer. This comes from the latest data analysis of the Phase 3 TROPiCS-02 clinical trial, which was published in The Lancet.
HCN Medical Memo
The study suggests sacituzumab govitecan offers a promising alternative to standard chemotherapy. The drug not only improves overall survival but also significantly reduces the risk of cancer progression or death. Given these compelling results, it may be time to consider sacituzumab govitecan as a standard treatment option for this patient population when the time comes.
- The overall survival rate for patients treated with sacituzumab govitecan was 14.4 months, compared to 11.2 months for those treated with standard chemotherapy.
- Patients treated with sacituzumab had a 34% lower risk of cancer progression or death.
- Sara Tolaney, MD, MPH, emphasized that the data “reinforce that sacituzumab govitecan is leading to improvements in both progression-free and overall survival.”
- The drug received FDA approval for the treatment of metastatic HR+/HER2- breast cancer in February of this year, following earlier data from the same study.
“These data reinforce that sacituzumab govitecan is leading to improvements in both progression-free and overall survival.”
– Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers at Dana-Farber; Senior Author of the Study
- The study involved 543 patients who had previously been treated with endocrine therapy and chemotherapy.
- Common adverse effects included neutropenia, diarrhea, nausea, alopecia, fatigue, and anemia, which were more prevalent in the sacituzumab govitecan group.
- Funding for the study was provided by Gilead.
More on Breast Cancer